Terms: = Kidney tumors AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
118 results:
1. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
[TBL] [Abstract] [Full Text] [Related]
2. Affinity fine-tuning anti-CAIX car-T cells mitigate on-target off-tumor side effects.
Wang Y; Buck A; Piel B; Zerefa L; Murugan N; Coherd CD; Miklosi AG; Johal H; Bastos RN; Huang K; Ficial M; Laimon YN; Signoretti S; Zhong Z; Hoang SM; Kastrunes GM; Grimaud M; Fayed A; Yuan HC; Nguyen QD; Thai T; Ivanova EV; Paweletz CP; Wu MR; Choueiri TK; Wee JO; Freeman GJ; Barbie DA; Marasco WA
Mol Cancer; 2024 Mar; 23(1):56. PubMed ID: 38491381
[TBL] [Abstract] [Full Text] [Related]
3. Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates.
Mandal A; Shetty J; Tran CA; Olson WC; Mandal M; Ban B; Pires ES; Adair SJ; Bauer TW; Slingluff CL; Herr JC
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485187
[TBL] [Abstract] [Full Text] [Related]
4. The TOPK Inhibitor HI-TOPK-032 Enhances car T-cell Therapy of Hepatocellular carcinoma by Upregulating Memory T Cells.
Zhang Q; Zheng F; Chen Y; Liang CL; Liu H; Qiu F; Liu Y; Huang H; Lu W; Dai Z
Cancer Immunol Res; 2024 May; 12(5):631-643. PubMed ID: 38407902
[TBL] [Abstract] [Full Text] [Related]
5. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
6. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell carcinoma.
Meng L; Collier KA; Wang P; Li Z; Monk P; Mortazavi A; Hu Z; Spakowicz D; Zheng L; Yang Y
Cells; 2023 Dec; 13(1):. PubMed ID: 38201238
[TBL] [Abstract] [Full Text] [Related]
7. Evolution of cell therapy for renal cell carcinoma.
Wang Y; Suarez ER; Kastrunes G; de Campos NSP; Abbas R; Pivetta RS; Murugan N; Chalbatani GM; D'Andrea V; Marasco WA
Mol Cancer; 2024 Jan; 23(1):8. PubMed ID: 38195534
[TBL] [Abstract] [Full Text] [Related]
8. The Effect of Histogram Analysis of DCE-MRI Parameters on Differentiating Renal tumors.
Li H; Zhao S; Fan HY; Li Y; Wu XP; Miao YP
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948477
[TBL] [Abstract] [Full Text] [Related]
9. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract] [Full Text] [Related]
10. car-T Therapy Targets Extra Domain B of Fibronectin Positive Solid Tumor Cells.
Tang J; Liu N; Zhu Y; Li Y; Zhao X
Immunol Invest; 2023 Nov; 52(8):985-996. PubMed ID: 37815216
[TBL] [Abstract] [Full Text] [Related]
11. HGF-Based car-T Cells Target Hepatocellular carcinoma Cells That Express High Levels of c-Met.
Ma H; Wei W; Liang D; Xu X; Yang D; Wang Q; Wang Y; Wei Q; Sun B; Zhao X
Immunol Invest; 2023 Nov; 52(6):735-748. PubMed ID: 37409941
[TBL] [Abstract] [Full Text] [Related]
12. Systemic Inflammatory Markers Predicting the Overall Survival of Patients Using Tyrosine Kinase Inhibitors in the First-line Treatment of Metastatic Renal Cell carcinoma.
Korkmaz M; Erylmaz MK
J Coll Physicians Surg Pak; 2023 Jun; 33(6):653-658. PubMed ID: 37300261
[TBL] [Abstract] [Full Text] [Related]
13. Anti-VEGF therapy improves EGFR-vIII-car-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
Dong X; Ren J; Amoozgar Z; Lee S; Datta M; Roberge S; Duquette M; Fukumura D; Jain RK
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898734
[TBL] [Abstract] [Full Text] [Related]
14. [Quantitative assessment of breast cancer resistance protein during pregnancy in rabbits].
Popova NM; Slepnev AA; Abalenikhina YV; Shchulkin AV; Rokunov ED; Yakusheva EN
Biomed Khim; 2023 Feb; 69(1):72-77. PubMed ID: 36857429
[TBL] [Abstract] [Full Text] [Related]
15. Acute kidney Injury in Cancer Immunotherapy Recipients.
Joseph A; Lafarge A; Azoulay E; Zafrani L
Cells; 2022 Dec; 11(24):. PubMed ID: 36552755
[TBL] [Abstract] [Full Text] [Related]
16. The tumor microenvironment and immune targeting therapy in pediatric renal tumors.
Hont AB; Dumont B; Sutton KS; Anderson J; Kentsis A; Drost J; Hong AL; Verschuur A
Pediatr Blood Cancer; 2023 May; 70 Suppl 2():e30110. PubMed ID: 36451260
[TBL] [Abstract] [Full Text] [Related]
17. Recurrent RET fusions in fibrosarcoma-like neoplasms in adult viscera: expanding the clinicopathological and genetic spectrum.
Zhao M; Yin X; He H; Xia Q; Ru G
Histopathology; 2023 Mar; 82(4):633-645. PubMed ID: 36443894
[TBL] [Abstract] [Full Text] [Related]
18. Nanobody-based car T cells targeting intracellular tumor antigens.
Li H; Zhong D; Luo H; Shi W; Xie S; Qiang H; Zhu L; Gao L; Liu J; Sun S; Ding Z; Yang X; Lu X
Biomed Pharmacother; 2022 Dec; 156():113919. PubMed ID: 36411612
[TBL] [Abstract] [Full Text] [Related]
19. Is CRP/Albumin Ratio (car) a New Parameter to be Added to Risk Stratification Systems in Metastatic Renal Cell carcinoma Patients?
Uzun M; Yildirim EC; Ekinci F; Semiz HS
J Coll Physicians Surg Pak; 2022 Nov; 32(11):1425-1429. PubMed ID: 36377009
[TBL] [Abstract] [Full Text] [Related]
20. Distal pancreatectomy with en bloc celiac axis resection (DP-car) using retroperitoneal-first laparoscopic approach (Retlap): A novel minimally invasive approach for determining resectability and achieving tumor-free resection margins of locally advanced pancreatic body cancer.
Kiguchi G; Sugioka A; Uchida Y; Mii S; Kojima M; Takahara T; Kato Y; Suda K; Uyama I
Surg Oncol; 2022 Dec; 45():101857. PubMed ID: 36252411
[TBL] [Abstract] [Full Text] [Related]
[Next]
